Medicina Crítica

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board

>Journals >Medicina Crítica >Year 2009, Issue 4

Montoya GC, Hernández LA, Villalobos SJA, Aguirre SJ, Franco GJ
Procalcitonin as an early diagnostic marker for septic shock
Rev Asoc Mex Med Crit y Ter Int 2009; 23 (4)

Language: Español
References: 21
Page: 211-217
PDF: 108.26 Kb.

Full text


Introduction: Procalcitonin (PCT) in early stages of shock, it may differentiate between septic and other causes of shock allowing an early treatment.
Objective: The objective of our study was to determine PCT usefulness as an early diagnostic marker for septic shock.
Methods: Prospective, longitudinal, observational study.
Results: 108 patients with an initial diagnosis of shock were included. PCT was determined at admittance and 5 days later. Sedimentation Rate (SR), C-reactive protein (CRP), leukocytes, APACHE II Score and SOFA score were also obtained.
At admittance, patients with septic shock presented higher PCT, SR, CRP and leukocyte values than other shock from other causes: PCT 4 (3-5) vs 0 (0-0) of septic shock vs. others respectively (p ‹ 0.01); SR 20 (15-25) in septic shock vs 9 (7-14) and p value ‹ 0.01; CRP 15 (10-19) vs 7 (4-10) respectively (p ‹ 0.01).
Conclusion: As expected, this study demonstrates that elevations of PCT in shock patients at admittance, is the best way to differentiate between septic shock and other causes of shock.

Key words: Procalcitonin, septic shock.


  1. Sierra R. C Reactive protein and procalcitonin as markers of infection, inflammatory response, and sepsis. Clinical Pulmonary Medicine 2007;14:314-320.

  2. Becker KL, Nylen ES, White JC et al. Clinical review 167: procalcitonin and the calcitonin gene family of peptides inflammation, infection and sepsis: a jouney from calcitonin back to its precursors. J Clin Endocrinol Metab 2004; 89:1512-1525.

  3. Meisner M. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta 2002;323:17-29.

  4. Uzzan B, Procalcitonin as a diagnostic test for sepsis in critically adults and after surgery or trauma: A systemic review and meta-analysis. Crit Care Med 2006;34:117-124.

  5. Jensen JU, Heslet L. Procalcitonin increase in early identification of critically ill patient at high risk of mortality. Crit Care Med 2006;36:122-132.

  6. Balc C, SurgertekinH, Gurses E, Surgertekin U. Kaptanoglu B. Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care 2003;7(1):85-90.

  7. Becker KL. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008;36:315-333.

  8. Tamg BMP, Eslick GD. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systemic review and meta-analysis. Lancet Infect Dis 2007;7:210-217.

  9. Huang DT, Weisfeld LA. Risk prediction with procalcitonin and clinical rules in community acquired Pneumonia. Annals of Emergency Medicine 2008;52:1117-1132.

  10. Martin GS, Maninno DM, Eaton S et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-1554.

  11. Bone RC, Balk RA, Cerra FB. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644.

  12. Levy MM, Fink MP, Marshall JC et al. 001 SCCM/ESICM/ACCP/ATS/SIS international Sepsis Definitions conference. Crit Care Med 2003;31:1250-1256.

  13. Assicot M, Gendrel D et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993;341:515-532.

  14. Cohen J, Brun-Buisson C, Torres A, Jorgensen J. Diagnosis of infection in sepsis: An evidence-based review. Crit Care Med 2004;32:S466-S494.

  15. Ugarte H, Silva E, Mercan D, De Mendoza A, Vicent JL. Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med 999;27:498-504.

  16. Ruokonen E, Ilkka L, Niskanen M, Takala J. Procalcitonin and neopterin as indicators of infection in critically ill patients. Acta Anaesthesiol Scand 2002;46:398-404.

  17. Selberg O, Hecker H, Martin M, Klos A, Bautsch W, Köhl J. Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6. Crit Care Med 2000;28:2793-2798.

  18. Harbarth S, Holeckova K, Froidevaux C, Pittet Didie, Ricou B et al. Diagnostic value of procalcitonin, Interleukin-6, and Interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001;164: 396-402.

  19. Tugrul S, Esen F, Celebi S, Ozcan PE, Akinci O, Cakar N et al. Reliability of procalcitonin as a severity marker in critically ill patients with inflammatory response. Anaesth Intensive Care 2002;30:747-754.

  20. Balci C, Sungurtekin H, Gürses E, Sungurtekin U, Kaptanoglu B. Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Critical Care 2003;7:85-90.

  21. Bochud PY, Boten M, Marchetti O, Calandra T. Antimicrobial therapy for patients with severe sepsis and septic shock: An evidence-based review. Crit Care Med 2004;32:S495-S512.

>Journals >Medicina Crítica >Year 2009, Issue 4

· Journal Index 
· Links 

Copyright 2019